Boston Financial Mangement LLC Makes New Investment in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

Boston Financial Mangement LLC bought a new position in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) in the 4th quarter, HoldingsChannel.com reports. The fund bought 28,248 shares of the biotechnology company’s stock, valued at approximately $141,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. State Street Corp grew its stake in shares of Aldeyra Therapeutics by 1.7% in the third quarter. State Street Corp now owns 973,908 shares of the biotechnology company’s stock valued at $5,249,000 after buying an additional 16,188 shares in the last quarter. Jacobs Levy Equity Management Inc. grew its stake in shares of Aldeyra Therapeutics by 163.4% in the third quarter. Jacobs Levy Equity Management Inc. now owns 476,949 shares of the biotechnology company’s stock valued at $2,571,000 after buying an additional 295,864 shares in the last quarter. International Assets Investment Management LLC grew its stake in shares of Aldeyra Therapeutics by 397.0% in the third quarter. International Assets Investment Management LLC now owns 287,287 shares of the biotechnology company’s stock valued at $15,480,000 after buying an additional 229,487 shares in the last quarter. Woodstock Corp grew its stake in shares of Aldeyra Therapeutics by 7.8% in the fourth quarter. Woodstock Corp now owns 194,919 shares of the biotechnology company’s stock valued at $973,000 after buying an additional 14,113 shares in the last quarter. Finally, Barclays PLC grew its stake in shares of Aldeyra Therapeutics by 280.1% in the third quarter. Barclays PLC now owns 65,561 shares of the biotechnology company’s stock valued at $353,000 after buying an additional 48,313 shares in the last quarter. Institutional investors and hedge funds own 59.71% of the company’s stock.

Aldeyra Therapeutics Stock Down 0.5 %

Shares of NASDAQ ALDX opened at $6.69 on Friday. Aldeyra Therapeutics, Inc has a twelve month low of $2.71 and a twelve month high of $6.92. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.18. The stock has a fifty day simple moving average of $5.36 and a 200-day simple moving average of $5.31.

Aldeyra Therapeutics Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.